Comparative safety of antiseizure medication monotherapy for major malformations.

Jacqueline M CohenSilje AlvestadCarolyn E CestaMarte-Helene BjørkMaarit K LeinonenMette NørgaardKristjana EinarsdóttirAnders EngelandMika GisslerØystein KarlstadKari KlungsøyrIngvild OdsbuJohan ReutforsRandi M SelmerTorbjörn TomsonSinna Pilgaard UlrichsenHelga ZoegaKari Furu

Published in: Annals of neurology (2022)

Topiramate is associated with an increased risk of MCM similar to that associated with valproate, but lower doses may mitigate the risks for both drugs. Conversely, we found no increased risks for lamotrigine, carbamazepine, oxcarbazepine, or levetiracetam, which is reassuring. This article is protected by copyright. All rights reserved.

Keyphrases

human health
healthcare
risk assessment
combination therapy
adverse drug
clinical trial
drug induced